How Medtech Founders Should Sequence a Medical Device Go-to-Market Strategy From Series A to Acquisition

Key Takeaways

• The medical device go-to-market strategy that compounds across stages is built around distribution efficiency, not around rep headcount
• Pre-Series-A founders who hit $30-50M in revenue before institutional capital arrives almost always engineered distribution efficiency first
• The acquisition multiple in a medtech exit is shaped by the go-to-market choices the founder made three to five years earlier
• A $67M delta between two reported exit numbers (Nalu's $533M vs $600M) traced back to commercial-execution earn-outs that depended on go-to-market discipline
• "Nobody finds you in medtech." The founders who win engineer a way to get found, a sentence Ray Cohen's MD&M 2026 co-panel repeated all year

You're at Series A.

The board has commercial milestones in the term sheet. The hire plan calls for a VP of Sales by quarter two, ten reps by quarter four, and revenue tripling by the end of next year.

The medical device go-to-market strategy on the wall behind the conference room shows funnel diagrams, territory maps, and CRM dashboards.

But the strategy doesn't say what stage-by-stage commercial discipline looks like in practice. So the team executes the same playbook regardless of where the company is in its arc. Series A reps run the same motion that Series C reps will run.

Pre-acquisition messaging looks like Series A messaging.

And the founders who were supposed to be moving toward an acquisition outcome instead spend two years burning cycles on a generic GTM motion that doesn't match the stage.

This post lays out a stage-by-stage medical device go-to-market strategy that compounds. The strategy is built around distribution efficiency, the variable Kyle Dempsey of MVM Partners named as the single biggest predictor of which clinical products turn into great businesses.

Distribution Efficiency Is the Variable That Predicts Everything

The most important metric in a medical device go-to-market strategy is not pipeline, MQLs, or rep productivity. It's distribution efficiency: the ratio of commercial output to the inputs (headcount, cash burn, marketing spend) it took to produce that output.

I interviewed Kyle Dempsey of MVM Partners on an episode about what MVM Partners really wants in a medtech company. MVM has been the first institutional investor in companies that already had $30 to $50 million in revenue before Series A.

The pattern Kyle named was specific:

"we've been the first institutional investor in a number of companies where we were the series A, but those companies were already doing 30, 40, 50 million of revenue because they had really capital efficient founders who figured out distribution efficiency."

— Kyle Dempsey, MVM Partners (The State of MedTech)

So distribution efficiency at Series A is what unlocks institutional capital on founder-friendly terms. Companies that haven't figured it out raise from investors who underwrite the work that should have been done before the round. The dilution penalty is real and compounding.

A medical device go-to-market strategy that prioritises distribution efficiency at every stage produces founder-friendly outcomes. A strategy that prioritises headcount growth and channel volume produces dilution.

Stage One Pre-Clinical to Clearance, Build the Distribution Hypothesis

The first stage of a medical device go-to-market strategy starts years before commercial launch. The work in this stage is hypothesis building, not tactical execution.

The founder needs to answer four questions before clearance:

1. Which clinician segment is the minimum viable category?

The answer should be one named procedure, one named clinician role, and one named institutional setting. Not "interventional cardiology." Specifically: "transcatheter mitral valve repair surgeons at high-volume valve centres."

2. What is the path-of-least-resistance to the first 20 deals?

The answer is usually a combination of existing KOL relationships, design-partner sites, and clinical-trial investigator centres. Founders who can't name the first 20 buyers by name before clearance are not ready to spend a single dollar on commercial infrastructure.

3. Who carries the brand into the room?

The answer is rarely the founder long-term. Pre-clearance is when the surgeon advisory board, the design partners, and the named-clinician champions get built. They become the brand carriers post-launch.

4. What are the unit economics at scale?

The answer needs to be modelled at three rep productivity levels: low (50% of target), mid (100%), and high (150%). The medical device go-to-market strategy should be financially defensible even at low rep productivity. If it only works at high, the strategy is hope, not a plan.

Stage Two Launch to $5M Revenue, Engineer Founder-Led Selling

The second stage is the first 18 months post-launch. The temptation in this stage is to hire reps fast and try to manufacture velocity. The right move is the opposite.

In this stage, the founder runs the commercial motion personally with one or two experienced commercial leaders. Every deal the founder closes is documentation work, the script, the demo, the proof structure, the objection handling.

The output of stage two is not revenue, it's a documented playbook the next stage can scale.

Founders who skip the documentation work in stage two end up in stage three with a sales team trying to recreate the founder's intuition.

They can't.

So the win rate collapses, churn spikes, and the company is forced to re-build the playbook from scratch with reps in the field, which costs another 12 months of runway.

The Ray Cohen and Tom West MD&M keynote went deep on this. I covered it in my recap of the MD&M 2026 keynote on $6.1B of combined exit experience.

One of the lines that landed hardest was about what most founders miss about exit math:

"Nalu Omar noted that we had an exit to Boston Scientific for $600 million, but if you look at LinkedIn, you might see in some places it says $533. Well, what's the delta there? That's $67 million worth of earn-outs tied to commercial-execution milestones."

— Tom West, CEO, Nalu Medical (The State of MedTech, MD&M 2026 Keynote)

So that $67M delta was the price of stage-two commercial discipline. The founders had documented enough of the commercial motion that the acquirer was willing to structure earn-outs around it. Companies whose stage-two motion lives only in the founder's head don't get those earn-outs structured.

Stage Three $5M to $30M Revenue, Replicate the Documented Motion

Stage three is the first multi-rep team.

The team is built on the playbook documented in stage two.

The hires are deliberate: one experienced commercial leader, then three to five reps in cities where champion relationships already exist.

The metric that matters in stage three is rep ramp time to productive. If new reps are productive within two quarters, the playbook is real and replicable.

If they take four or more quarters to ramp, the playbook didn't get documented properly in stage two. The remedy is to pause hiring and rebuild documentation, not to push through with more reps.

Stage three is also the stage where the medical device go-to-market strategy starts touching channels the founder hasn't run before, payer relationships, IDN contracts, Value Analysis Committee processes, KOL programs.

Those motions need their own playbooks built by people who've run them before. So the second senior hire after the commercial leader is usually a market-access lead who understands the payer and IDN side.

Stage Four $30M to Acquisition, Engineer the Exit Outcome

The final stage of a medical device go-to-market strategy is the one most founders treat as somebody else's job. The exit work is a go-to-market function. It runs for three to five years before the acquisition closes, long before a banker is in the room.

I covered the engineering of the exit outcome on an episode about 7 lessons from $17B in medtech exits:

"Nobody finds you in medtech exits. You have to engineer a way to get found. And that involves crafting the right narrative. Founders who have done it really the best spend years building that outcome, showing that you don't need to wait."

— The State of MedTech, "7 Lessons from $17B in Medtech Exits"

The "engineering a way to get found" work in stage four is narrative work.

It's the published case studies, the named-customer references, the analyst coverage, the strategic-partner relationships, and the consistent industry presence that signal to acquirers that the company is a serious commercial business, not a science project with promising data.

I also interviewed Tom West, then-CEO of Nalu Medical, on the investor truth every medtech CEO needs episode.

He framed the same idea in distribution-efficiency terms:

"the main difference between a great clinical product and a great business is whether the team can reach distribution efficiency."

— Tom West, CEO, Nalu Medical (The State of MedTech)

So the exit outcome is shaped by the distribution-efficiency choices in stages two and three.

Founders who skipped distribution efficiency in earlier stages end up in stage four trying to manufacture a narrative that the underlying numbers don't support. The acquirer's diligence team finds the gap quickly. The multiple compresses.

What This Means for Medtech Founders

In my experience working with medtech founders, the medical device go-to-market strategy conversation almost always conflates the four stages.

Series A founders run Series C playbooks. Pre-acquisition founders behave like they're still pre-revenue. And the result is a generic GTM motion that doesn't fit any stage well.

So the better practice is to name the current stage explicitly, identify what the next stage needs, and run the playbook that fits the current stage.

The founders who do this consistently end up at MVM-style outcomes, $30M+ in revenue before institutional capital arrives, founder-friendly Series A terms, and a stage-four narrative that produces acquirer multiples worth fighting for.

For more on the upstream work that has to happen before any stage runs cleanly, read the medtech commercialisation strategy framework. And for the operator-level view of how stage-four exit engineering compounds into multi-billion-dollar outcomes, the medtech exit playbook walks through what the founders who got there did differently.

Frequently Asked Questions

What is a medical device go-to-market strategy?

A medical device go-to-market strategy is the stage-by-stage plan that defines how a medtech company will move from clearance to scale revenue. The plan covers segment selection, channel mix, sales motion design, KOL engagement, payer and IDN access, and commercial team build.

The strongest medical device go-to-market strategies run distinct motions across four stages: pre-clinical to clearance, launch to $5M revenue, $5M to $30M, and $30M to acquisition.

How long does a medical device go-to-market strategy take to produce results?

Pre-traction medtech companies completing the first stage from scratch typically need 12 to 18 months before the first commercial-launch motion can start producing measurable revenue. Stages two and three each typically run 18 to 24 months. Stage four (the engineered exit work) runs three to five years.

Founders who try to compress the stages, by hiring reps before the playbook is documented, or running exit motions before the commercial business is real, typically lose 12 to 18 months of runway to motion that produces no compounding pipeline.

Why does distribution efficiency matter more than rep headcount in a medical device go-to-market strategy?

Distribution efficiency predicts whether a company can scale revenue without proportional capital injection. Companies with high distribution efficiency raise institutional capital on founder-friendly terms, attract acquirer interest on stronger multiples, and survive market downturns.

Companies that depend on rep-headcount growth to generate revenue are vulnerable to dilution, rep churn, and acquirer scepticism.

Distribution efficiency is also the variable that institutional investors like MVM Partners use to evaluate Series A opportunities, companies that hit $30M to $50M in revenue pre-Series A almost always did it on distribution efficiency, not on rep volume.

How does a medical device go-to-market strategy connect to a medtech exit outcome?

The acquisition multiple in a medtech exit is shaped by the go-to-market choices the founder made three to five years earlier. Stage four exit engineering, analyst coverage, named-customer references, published case studies, strategic-partner relationships, only produces multiple expansion if stages two and three built the underlying commercial business the narrative is describing.

Founders who skip stages two and three and try to manufacture the exit narrative from scratch face diligence-team scepticism, multiple compression, and earn-out-heavy structures that put the bulk of the deal value at risk.

Listen to the Full Conversations

The episodes referenced in this post are available on The State of MedTech. Subscribe wherever you listen to podcasts.

• What MVM Partners Really Wants in a MedTech Company with Kyle Dempsey
• MD&M 2026 Keynote: $6.1B Advice from Ray Cohen and Tom West
• 7 Lessons from $17B in Medtech Exits That Every Founder Must Know
• The Investor Truth Every MedTech CEO Needs (Tom West, Nalu Medical)

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry. He works with medtech founders and commercial leaders on market engineering, commercialisation strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.